Inhibitors that target key components of this pathway, including PI3K, AKT and mammalian target of rapamycin (mTOR), are being actively developed. Some of them have reached clinical trials in ...

The frequency of high blood glucose among patients receiving PI3K/Akt inhibitors to treat breast cancer has some oncologists ...